Ai‐Wu Ke

机构：Fudan University Shanghai Cancer Center, Ministry of Education · ORCID：0000-0002-7964-6909

发表论文 181 篇 · 总被引 9590 次 · h-index 51

代表论文

• PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy (2023 · Advanced Science · 被引 85)
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma (2024 · Nature Communications · 被引 48)
• WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas (2023 · Cancer Letters · 被引 27)
• Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy (2023 · Cancer Letters · 被引 22)
• Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma (2023 · International Immunopharmacology · 被引 16)
• Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors (2024 · Radiotherapy and Oncology · 被引 14)